Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.

Molecular cancer therapeutics - 1 Dec 2010

Huang Jen-Ming, Sheard Michael A, Ji Lingyun, Sposto Richard, Keshelava Nino

Abstract excerpt

As p53 loss of function (LOF) confers high-level drug resistance in neuroblastoma, p53-independent therapies might have superior activity in recurrent neuroblastoma. We tested the activity of vorinostat, a histone deacetylase inhibitor, and flavopiridol, a pan-Cdk inhibitor, in a panel of multidrug-resistant neuroblastoma cell lines that included lines with wild-type (wt) and transcriptionally active TP53 (n =...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flavonoids

Share to G2 Phase

Share to Histone Deacetylase Inhibitors

Share to Hydroxamic Acids

Share to Piperidines

Share to Vorinostat

Source

Open in PubMed Open full text

Identifiers

PMID: 21159612
DOI: 10.1158/1535-7163.MCT-10-0562
PMCID: PMC8312524

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.PMID 21159612Read ↗

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.Semantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.Semantic proximity Read ↗

The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.Semantic proximity Read ↗

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.Semantic proximity Read ↗

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.Semantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.Semantic proximity Read ↗

p53 determines multidrug sensitivity of childhood neuroblastoma.Semantic proximity Read ↗

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.